Status: Recruiting
Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients
The purpose of this study is to evaluate the safety and tolerability of DF-003 in retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache (ROSAH) syndrome patients.
Participants needed: 12
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)Updated: Jun 5, 2026Locations: 5
Eligibility criteria
Sufficient understanding of the purpose and procedures required for the study. [+5]
Males who plan to father a child or donate sperm while enrolled in this study or... [+17]